Cancer of the Oral Cavity Clinical Trial
Official title:
Prospective Evaluation of Quality of Life and Development of Measures in Patients With Cancer of the Oral Cavity
The purpose of this study is to learn more about the quality of life and emotional changes that patients experience during their treatment for cancer of the mouth. We want to learn more about the emotional and quality of life problems that occur during and after treatment. This will help us better understand these complex issues and improve treatment.
Status | Completed |
Enrollment | 164 |
Est. completion date | October 2014 |
Est. primary completion date | October 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: PATIENT INCLUSION CRITERIA FOR THE LONDITUDINAL STUDY: - Carcinoma of the oral cavity including one or more of the following anatomic sub-sites: Anterior 2/3rds of the tongue, the floor of the mouth, the upper and lower gums, buccal mucosa, retromolar trigone, hard palate and minor salivary glands. - Surgically resectable disease in the oral cavity and the neck. - Patients with prior cancers other than Head and Neck cancers who are currently in remission, have no evidence of disease and are not undergoing any active chemotherapy or radiation therapy. Exclusion Criteria: EXCLUSION FOR THE LONDITUDINAL STUDY: - Primary tumor of the lips (these are skin cancers). - Surgical treatment excluding diagnostic biopsy of the primary site or biopsy of neck node/s prior to referral to MSKCC. - Surgically unresectable disease in the neck; including carotid encasement, massive dermal infiltration, and other clinical and radiographic findings which would preclude surgically resectable nodal disease in the neck, prior to initiation of treatment. - Evidence of distant metastases by clinical or radiographic examination. - Patients with more than one simultaneous primary tumor. - Patient unable to read or comprehend the content of the questionnaires due to language barriers or psychiatric disorders. PATIENT INCLUSION CRITERIA FOR THE CROSS-SECTIONAL STUDY: - Upper aerodigestive squamous cell carcinoma, including the oropharynx, hypopharynx and larynx - newly diagnosed or recurrent cancers. - Newly diagnosed and recurrent carcinoma of the oral cavity including one or more of the following anatomic sub-sites: Anterior 2/3rds of the tongue, the floor of the mouth, the upper and lower gums, buccal mucosa, retromolar trigone, hard palate and minor salivary glands. EXCLUSION CRITERIA FOR THE CROSS-SECTIONAL STUDY: - Primary tumor of the lips (these are skin cancers). - Patient unable to read or comprehend the content of the questionnaires due to language barriers or psychiatric disorders. |
Observational Model: Case-Crossover, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Memorial Sloan Kettering Cancer Center | Monash University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | is to assess quality of life and psychosocial adaptation in patients undergoing treatment for cancer of the oral cavity so that we can develop empirically-informed interventions to improve the adaptation of these patients. | conclusion of study | No | |
Secondary | Validate two new measures of psychosocial adjustment in patients treated for cancer of the oral cavity and upper aerodigestive SCC: The Shame and Stigma in Head and Neck Cancer Scale and the Demoralization Scale | conclusion of study | No | |
Secondary | Assess patterns of tobacco and/or alcohol use in cancer of the oral cavity survivors. | conclusion of the study | No | |
Secondary | Assess the impact of lifestyle and socio-economic issues on post-therapy quality of life. | conclusion of the study | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00117572 -
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
|
Phase 3 | |
Completed |
NCT00462735 -
Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer
|
Phase 2 |